Barinthus Biotherapeutics plc - American Depositary Shares — Liquidità (NASDAQ:BRNS)

Financials

Flusso di cassa derivante dalle attività operative -32.58 M-14.43 M-50.92 M-28.94 M-47.98 M -47.98 M Flussi di cassa derivanti dalle attività di investimento -12.91 M-5.75 M-5.41 M-892 K416 K 416 K Liquidità derivante dalle attività di finanziamento 222.74 M325 K1.87 M2.16 M2 000 2 000 Liquidità libera -33.73 M-20.57 M-56.34 M-29.83 M-48.02 M -48.02 M

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics plc is a biotechnology company developing immunotherapies for infectious diseases, cancer and autoimmune diseases such as hepatitis B, HPV and prostate cancer. Formerly known as Vaccitech plc, in November 2023 the company announced that it had renamed itself to Barinthus Biotherapeutics plc. As of 2024, the company employs more than 100 people.

BRNS

Financials

Barinthus Biotherapeutics plc - American Depositary Shares

Notizie

Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Buy: What Does It Mean for the Stock?

Barinthus Bio riporta dati iniziali positivi dalla sperimentazione per la celiachia

Barinthus Bio reports positive initial data from celiac therapy trial

H.C. Wainwright riconferma il rating Buy per le azioni di Barinthus Biotherapeutics

Barinthus Biotherapeutics stock rating reiterated at Buy by H.C. Wainwright

Barinthus Bio and Clywedog to merge in all-stock deal

Barinthus Biotherapeutics’ CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025